A study comparing the efficacy, safety, tolerability, pharmacokinetics and immunogenicity between AVT04 (ustekinumab biosimilar) and Janssen’s Stelara® in patients with moderate-to-severe chronic plaque psoriasis (PsO) has been published. The authors report that the study demonstrates the therapeutic equivalence between AVT04 and Stelara® in patients with moderate-to-severe chronic PsO, with similar safety and tolerability.
Alvotech announced clinical studies supporting biosimilarity and comparability of ATV04 and Stelara® on 17 March 2023, and the data was presented at the American Academy of Dermatology Annual Meeting on 17-21 March in New Orleans.
Print Page Mail Article